News
NeuroSense Presents Data Validating Phase 2b Topline Readout During Emerging Science Presentation At American Academy Of Neurology Annual Meeting
18 Apr 24
Biotech, News, General
Reported Earlier, NeuroSense Therapeutics Prices $4.5M Registered Direct Offering Of 2.98M Shares And Concurrent Private Placement
11 Apr 24
News
NeuroSense Collaborates With Lonza To Identify Exosome-Based Biomarkers For Advance Neurodegenerative Disease Treatments And Diagnostics
9 Apr 24
Biotech, News, General
NeuroSense Therapeutics Q4 EPS $(0.16) Beats $(0.23) Estimate
5 Apr 24
Earnings, Earnings Beats, News
NeuroSense Reports Results From Its ALS Phase 2b PARADIGM Trial
21 Feb 24
Biotech, News, General
Press releases
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
12 Apr 24
Press Releases
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
10 Apr 24
Offerings, Press Releases
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
9 Apr 24
Press Releases
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
5 Apr 24
Earnings, Press Releases
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
21 Feb 24
Press Releases
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
7 Feb 24
Press Releases
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
30 Jan 24
News, Press Releases